0000000000985701

AUTHOR

L. Tassi

showing 3 related works from this author

Measurement of the K-S mean lifetime from pi(+)pi(-) and pi(0)pi(0) decays using K-L decays to determine the acceptance

1997

A precision measurement of the KS mean lifetime has been performed by comparing, in the same experimental setup, the distributions of two-pion decays of neutral kaons produced by high energy proton-beryllium interactions in two targets at a relative distance variable between 112 and 160 m. The value obtained combining the results from π+π- and π0π0 decays is τS = (0.8971 ± 0.0021) 10-10 s. © Springer-Verlag 1997.

PhysicsNuclear physicsHigh energyPhysics and Astronomy (miscellaneous)High Energy Physics::ExperimentAtomic physicsNuclear ExperimentValue (mathematics)Variable (mathematics)ZEITSCHRIFT FUR PHYSIK C-PARTICLES AND FIELDS
researchProduct

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, RealWorld Study

2022

Introduction: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Most real-world research on BRV has focused on refractory epilepsy. The aim of this analysis was to assess the 12-month effectiveness and tolerability of adjunctive BRV when used as early or late adjunctive treatment in patients included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Methods: BRIVAFIRST was a 12-month retrospective, multicenter study including adult patients prescribed adjunctive BRV. Effectiveness outcomes included the rates of sustained seizure response, sustained seizure freedom, and treatment discontinua…

Antiseizure medicationFocal seizuresAntiseizure medication; Brivaracetam; Epilepsy; Focal seizures.Antiseizure medication; Brivaracetam; Epilepsy; Focal seizures;EpilepsyNeurologyBrivaracetamSettore MED/26 - NeurologiaNeurology (clinical)Antiseizure medication; Brivaracetam; Epilepsy; Focal seizuresSettore MED/26Settore MED/39 - Neuropsichiatria Infantile
researchProduct

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)

2021

Background: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile. Objective: This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice. Methods: The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes includ…

medicine.medical_specialtybusiness.industryContext (language use)Brivaracetammedicine.diseaseDiscontinuationlaw.inventionPsychiatry and Mental healthEpilepsyRandomized controlled trialTolerabilityfocal epilepsy add-on therapy seizurelawConcomitantInternal medicineMedicinePharmacology (medical)Neurology (clinical)LevetiracetamOriginal Research Articlebusinessmedicine.drug
researchProduct